Poniecka Agnieszka, Smolewska Elżbieta
Department of Paediatric Cardiology and Rheumatology, Medical University of Lodz, Poland.
Pediatric Center Maria Konopnicka, Central Clinical Hospital of the Medical University of Lodz, Poland.
Reumatologia. 2021;59(1):47-57. doi: 10.5114/reum.2021.102871. Epub 2021 Feb 28.
Multisystem inflammatory syndrome in children is a newly described condition temporarily associated with severe acute respiratory syndrome coronavirus 2. The primary observations indicated coronavirus disease 2019 infection in children to be mild. However, recent reports have revealed a correlation between multisystem inflammatory symptoms and coronavirus infection. The manifestation of the disease is similar to Kawasaki disease, toxic shock syndrome and macrophage activation syndrome. Treatment includes intravenous corticosteroids, immunoglobulin and biological therapy (anakinra, tocilizumab, infliximab). In this article we compare world reports of multisystem inflammatory syndrome in children to case reports of two patients who were hospitalized recently at the Department of Paediatric Cardiology and Rheumatology. In the course of diagnostics they presented numerous symptoms which required differentiation from multisystem inflammatory syndrome in children.
儿童多系统炎症综合征是一种新描述的病症，暂时与严重急性呼吸综合征冠状病毒2相关。初步观察表明，儿童感染2019冠状病毒病通常症状较轻。然而，最近的报告显示多系统炎症症状与冠状病毒感染之间存在关联。该疾病的表现类似于川崎病、中毒性休克综合征和巨噬细胞活化综合征。治疗方法包括静脉注射皮质类固醇、免疫球蛋白和生物疗法（阿那白滞素、托珠单抗、英夫利昔单抗）。在本文中，我们将全球关于儿童多系统炎症综合征的报告与最近在儿科心脏病学和风湿病科住院的两名患者的病例报告进行比较。在诊断过程中，他们出现了许多需要与儿童多系统炎症综合征相鉴别的症状。
